FFRangio System vs Tempus ECG-AF
AI Verdict
Choose FFRangio System if…
Choose the CathWorks FFRangio System if you are a cardiologist performing percutaneous coronary intervention (PCI) and require real-time, wire-free, and drug-free functional assessment of coronary artery disease. This system is ideal for optimizing PCI decisions, confirming treatment effectiveness, and assessing residual ischemia directly in the cath lab.
View FFRangio System →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to identify patients aged 65 or older, without a pre-existing AF diagnosis, who are at an increased risk of developing atrial fibrillation/flutter within the next 12 months. This AI-based algorithm supports earlier identification and follow-up strategies, integrating with existing 12-lead ECG recordings to aid in proactive patient management.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FFRangio System | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Contact vendor |
| Deployment | SaaS, on-prem, hybrid | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FFRangio SystemTool A, the FFRangio System, emphasizes an 'intuitive user interface' and 'seamless integration' within the cath lab, providing real-time, interactive 3D FFR guidance during a procedure. This direct, visual, and interactive feedback during a critical intervention suggests a high degree of usability for the clinician in a procedural setting. Tool B, while integrated as a software solution, focuses on algorithmic analysis rather than real-time interactive guidance.
Clinical Value
FFRangio SystemThe FFRangio System offers a significant advancement by providing 'wire-free and drug-free 3D FFR guidance,' eliminating the need for invasive pressure wires and drugs during PCI decisions. This reduces procedural invasiveness and potential risks for patients with coronary artery disease, directly impacting treatment decisions in real-time. While Tempus ECG-AF provides valuable early risk stratification for AF, Tool A's direct impact on an interventional procedure represents a more immediate and tangible clinical benefit in the moment of care.
Pricing & Value
Tempus ECG-AFTempus ECG-AF clearly outlines its financial value by stating the availability of CMS reimbursement with specific CPT codes and a Medicare rate of $128.90, effective January 1, 2025. This transparency and established reimbursement pathway provide a clear economic advantage and value proposition for healthcare providers. In contrast, the FFRangio System only states 'contact for pricing,' offering no public details on cost or potential reimbursement.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF explicitly confirms it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, which are critical requirements for enterprise adoption in healthcare. Its deployment as a software solution integrated into existing facility systems also suggests easier scalability and management. The FFRangio System's HIPAA compliance is 'unknown' and BAA is only 'likely' but not explicitly stated, and its on-premise integration with cath lab equipment might present more complex deployment and IT management considerations for large organizations.
Innovation
FFRangio SystemThe FFRangio System introduces a highly innovative 'wire-free and drug-free 3D FFR guidance' approach, fundamentally transforming how functional assessment is performed during PCI procedures. This represents a significant paradigm shift in interventional cardiology by eliminating invasive components and providing real-time, comprehensive data. While Tempus ECG-AF's predictive AI for AF risk is also innovative, Tool A's method of non-invasive, real-time physiological assessment in the cath lab is a more disruptive procedural innovation.
Support & Docs
TieNeither the provided structured facts nor readily available public web searches offer specific, comparable details regarding the support services, documentation quality, or service level agreements for either the FFRangio System or Tempus ECG-AF. Without this information, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FFRangio System | Tempus ECG-AF |
|---|---|---|
| Name | FFRangio System | Tempus ECG-AF |
| Company | CathWorks | Tempus AI, Inc. |
| Primary Function | Delivers wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Key Technology | Wire-free and drug-free 3D FFR guidance, Artificial intelligence aids in quick angiogram analysis | AI-based algorithm for 12-lead ECG analysis |
| Target Condition | Coronary Artery Disease | Risk of new onset Atrial Fibrillation (AF) |
| Target Patient Population | Patients with coronary artery disease | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery |
Videos
Demos, reviews, and walkthroughs featuring FFRangio System and Tempus ECG-AF.